Biosimilars in paediatric inflammatory bowel disease

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 35

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Sep 21, 2018; 24(35): 4021-4027
Published online Sep 21, 2018. doi: 10.3748/wjg.v24.i35.4021

Table 3 Biosimilars approved by the European Medicinal Agency in use among inflammatory bowel disease patients[38-40]

Citation: Sieczkowska-Golub J, Jarzebicka D, Oracz G, Kierkus J. Biosimilars in paediatric inflammatory bowel disease. World J Gastroenterol 2018; 24(35): 4021-4027
URL: https://www.wjgnet.com/1007-9327/full/v24/i35/4021.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i35.4021

Sieczkowska-Golub J, Jarzebicka D, Oracz G, Kierkus J. Biosimilars in paediatric inflammatory bowel disease. World J Gastroenterol 2018; 24(35): 4021-4027 [PMID: 30254406 DOI: 10.3748/wjg.v24.i35.4021]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.